Currently Druggable in Melanoma

A Drug Target Competitive Analysis

Product Code BSK00066
Publication Date October 2008
Publisher Bioseeker
Product Type Report
Pages 268
ISBN Number not applicable
Change currency
PDF £1,620.00 €1,951 $2,562 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Currently Druggable in Melanoma

A Drug Target Competitive Analysis

This report aims to analyze the current and future potential of melanoma pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within melanoma drug development. It allows you to pin-point which competitors drugs' clinical out-come may have bearing on your own drug development and who are developing sequels to successful drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the melanoma field and identified 118 drug targets belonging to 124 drugs. This report, Currently Druggable in Melanoma: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of melanoma drugs.

In the report, BioSeeker reports on 94 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 124 melanoma drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and R&D approach. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of melanoma drugs. No less than 207 target-target interactions were recognized among and between 85 of the 118 included melanoma drug targets.

Why You Should Own Your Own Copy of this Report:

268+ pages, with more than 50 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
A 124 melanoma drugs analysis, under development by 95 investigators
118 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other melanoma drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
A unique drug target combination breakdown of melanoma drugs into R&D approaches
Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
Pathway profiling of melanoma drug targets
Compound strategies based on sub-cellular localization of drug targets
Expression levels of identified drug targets in malignant melanoma tissue
Structure based drug design in melanoma
Pin-point which competitor drugs' clinical out-come may have bearing on your own drug development
Who are working on sequels to blockbuster drugs?
Locate white-spots in the competitive landscape, giving you little or no competition
In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

Contents

  • 1 Executive Summary
  • 2 About Cancer Highlights
  • 3 Methodologies
  • 4 Table of Contents
    • 4.1 List of Figures
    • 4.2 List of Tables
  • 5 How to Use this Report
  • 6 Compound Strategies based on Sub-Cellular Localization of Melanoma Drug Targets
    • 7 The Cancer Genome Project and Melanoma Targets
    • 7.1 Melanoma Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
  • 8 Expression Levels of Identified Drug Targets in Melanoma Tissue
  • 9 Pathway Analysis of Melanoma Drugs
  • 10 Target-Target Interactions among Identified Melanoma Targets
  • 11 Structure-based Drug Design in Melanoma is Stimulated by Available Structure Data on Biological Targets
  • 12 Drug Target Profiles of Melanoma Drugs
    • 12.1.1 Auxiliary Transport Protein Activity Targets
    • 12.1.2 Carboxy-Lyase Activity Targets
    • 12.1.3 Catalytic Activity Targets
    • 12.1.4 Cell Adhesion Molecule Activity Targets
    • 12.1.5 Chaperone Activity Targets
    • 12.1.6 Cofactor Binding Targets
    • 12.1.7 Cytokine Activity Targets
    • 12.1.8 DNA Binding Targets
    • 12.1.9 DNA Repair Protein Targets
    • 12.1.10 DNA Topoisomerase Activity Targets
    • 12.1.11 DNA-Directed DNA Polymerase Activity Targets
    • 12.1.12 DNA-Methyltransferase Activity Targets
    • 12.1.13 Extracellular Matrix Structural Constituent Targets
    • 12.1.14 G-Protein Coupled Receptor Activity Targets
    • 12.1.15 Growth Factor Activity Targets
    • 12.1.16 Hydrolase Activity Targets
    • 12.1.17 Kinase Regulator Activity Targets
    • 12.1.18 Lipase Activity Targets
    • 12.1.19 MHC Class I Receptor Activity Targets
    • 12.1.20 Molecular Function Unknown Targets
    • 12.1.21 Motor Activity Targets
    • 12.1.22 Oxidoreductase Activity Targets
    • 12.1.23 Protein Binding Targets
    • 12.1.24 Protein Serine/Threonine Kinase Activity Targets
    • 12.1.25 Protein Threonine/Tyrosine Kinase Activity Targets
    • 12.1.26 Protein Tyrosine Phosphatase Activity Targets
    • 12.1.27 Receptor activity
    • 12.1.28 Receptor Binding Targets
    • 12.1.29 Receptor Signaling Complex Scaffold Activity Targets
    • 12.1.30 Transcription Factor Activity Targets
    • 12.1.31 Transcription Regulator Activity Targets
    • 12.1.32 Transferase Activity Targets
    • 12.1.33 Translation Regulator Activity Targets
    • 12.1.34 Transmembrane Receptor Activity Targets
    • 12.1.35 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
    • 12.1.36 Transporter Activity Targets
  • 13 The Drug-Target Interactome
  • 14 The Progression and Maturity of Melanoma Targets
    • 14.1 Target Profiles of Melanoma Drugs in Pre-Registration to Marketed
    • 14.2 New and Unique Melanoma Targets in Phase III Clinical Development
    • 14.3 New and Unique Melanoma Targets in Phase II Clinical Development
    • 14.4 New and Unique Melanoma Targets in Phase I Clinical Development
    • 14.5 New and Unique Melanoma Targets in Preclinical Development
    • 14.6 Development Profiles of All Melanoma Target Combinations
  • 15 Targets by R&D Approach in Melanoma
    • 15.1 Small Molecules
      • 15.1.1 Background
      • 15.1.2 Targets in Melanoma
    • 15.2 Peptide/Protein Drugs
      • 15.2.1 Background
      • 15.2.2 Targets in Melanoma
    • 15.3 Monoclonal Antibodies and Antibody-Like Structures
      • 15.3.1 Background
      • 15.3.2 Targets in Melanoma
    • 15.4 Nucleic Acid Therapies
      • 15.4.1 Background
      • 15.4.2 Targets in Melanoma
    • 15.5 Gene Therapy
      • 15.5.1 Background
      • 15.5.2 Targets in Melanoma
    • 15.6 Drug Delivery and Nanotechnology
      • 15.6.1 Background
      • 15.6.2 Targets in Melanoma
  • 16 Melanoma Targets by Companies
    • 16.1 Australia
    • 16.2 Canada
    • 16.3 Denmark
    • 16.4 France
    • 16.5 Germany
    • 16.6 Israel
    • 16.7 Italy
    • 16.8 Japan
    • 16.9 Norway
    • 16.10 South Korea
    • 16.11 Spain
    • 16.12 Sweden
    • 16.13 Switzerland
    • 16.14 United Kingdom
    • 16.15 USA
  • 17 Disclaimer
  • 18 Drug Index
  • 19 Company Index
  • List of Figures
    • Figure 1: Distribution of Compound Types among Melanoma Drugs
    • Figure 2: Primary Sub-cellular Localization of Drug Targets
    • Figure 3: Visualization of Target-Target Interactions Among Melanoma Drug Targets
    • Figure 4: The Drug-Protein Interactome of Melanoma Drugs
    • Figure 6: Head-to-Head Targeting Interactome of Melanoma Drugs
  • List of Tables
    • Table 1: Compound Strategies based on Sub-Cellular Localization of Melanoma Drug Targets
    • Table 2: Drug Targets of Melanoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
    • Table 3: Expression Levels of Identified Drug Targets in Malignant Melanoma Tissue
    • Table 4: Pathway Summary
    • Table 5: Drug Targets without any Identified Assigned Pathways
    • Table 6: Pathway Profile According to BioCarta of Melanoma Drug Targets
    • Table 7: Pathway Profile According to KEGG of Melanoma Drug Targets
    • Table 8: Pathway Profile According to NetPath of Melanoma Drug Targets
    • Table 9: Target-Target Interactions among Melanoma Drug Targets
    • Table 10: Identity of Melanoma Drug Targets with Available Biological Structures
    • Table 11: Overview of Drug Target Profile Themes
    • Table 12: Drug-Protein Interactome Clusters
    • Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug Target Mixes by Developmental Stage
    • Table 14: Top 5 Competitive Melanoma Targets
    • Table 15: Target Profiles of Melanoma Drugs in Pre-Registration to Marketed
    • Table 16: New and Unique Melanoma Targets in Phase III Clinical Development
    • Table 17: New and Unique Melanoma Targets in Phase II Clinical Development
    • Table 18 New and Unique Melanoma Targets in Phase I Clinical Development
    • Table 19: New and Unique Melanoma Targets in Preclinical Development
    • Table 20: The Progression, Maturity and Competitive Comparison of Melanoma Drug Targets in Development
    • Table 21: Number of Melanoma Drug Target Mixes Reported by Line of Therapy
    • Table 22: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Melanoma by Drug Target
    • Table 23: Drug Targets of Small Molecule Drugs in Melanoma
    • Table 24: Mechanistic Relationship between Small Molecule Drugs in Melanoma
    • Table 25: Drug Targets of Peptide Based Drugs in Melanoma
    • Table 26: Drug Targets of Protein Based Drugs in Melanoma
    • Table 27: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Melanoma
    • Table 28: Drug Targets of Nucleic Acid Therapies in Melanoma
    • Table 29: Vectors in Gene Therapy
    • Table 30: Drug Targets of Gene Therapies in Melanoma
    • Table 31: Drug Targets with New Drug Delivery Strategies in Melanoma
    • Table 32: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Australia
    • Table 33: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Canada
    • Table 34: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Denmark
    • Table 35: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in France
    • Table 36: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Germany
    • Table 37: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Israel
    • Table 38: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Italy
    • Table 39: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Japan
    • Table 40: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Norway
    • Table 41: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in South Korea
    • Table 42: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Spain
    • Table 43: Melanoma Drugs with Drug Target Mix and Developmental Projects by Companies in Sweden
    • Table 44: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Switzerland
    • Table 45: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in United Kingdom
    • Table 46: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in USA